3-(3,5-二氯苯基)-丙醛 | 95333-97-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(3,5-二氯苯基)-丙醛
• 英文名称: 3-(3,5-dichlorophenyl)propanal
• CAS: 95333-97-4
• 化学式: C₉H₈Cl₂O
• mdl: MFCD07772915
• 分子量: 203.068
• InChiKey: GJSMIWZLHQYITP-UHFFFAOYSA-N

物化性质

• 沸点：
  271.0±25.0 °C(Predicted)
• 密度：
  1.269±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2913000090

反应信息

• 作为反应物：
  描述：

  3-(3,5-二氯苯基)-丙醛 在 sodium tetrahydroborate 作用下， 以 乙醇 、 正己烷 为溶剂， 反应 19.0h， 生成 N-<3-(3,5-dichlorophenyl)propyl>aminoacetaldehyde dimethyl acetal
  参考文献：
  名称：

  Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site

  摘要：

  1-Aralkylimidazole-2-thiones have been shown to be potent multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1). In the present study, a series of 1-benzylimidazole-2-thiones was prepared to explore the effects of substitution in the benzyl ring on the inhibition of DBH. A detailed structure-activity relationship for in vitro activity was discovered and this was shown by a modified Hansch analysis to correlate (r = 0.91) with four key structural features of the benzyl ring: the presence of a hydroxyl at the 4-position, molar refractivity at the 3-, 4-, and 5-positions, inductive effects of the substituents at the 3-, 4-, and 5-positions, and pi-electron density. The affinity (Kis) of eight substituted inhibitors for DBH was shown to correlate (r = 0.75) with the affinity (KD) of comparably substituted tyramines for the ternary DBH-oxygen-tyramine complex. This correlate is used to support the hypothesis that binding of inhibitor to DBH occurs in a fashion that mimics the binding of tyramine substrates. The most potent inhibitors were selected for study in vivo in the spontaneously hypertensive rat model of hypertension. The changes in vascular dopamine and norepinephrine levels that resulted from oral administration of the inhibitors corresponded to the observed reduction in mean arterial blood pressure. A divergence between in vitro potency and in vivo efficacy upon oral dosing was noted and is suggested to result from an in vivo metabolic conjugation of the phenolic group of inhibitor.

  DOI：

  10.1021/jm00386a008
• 作为产物：
  描述：

  3-(3,5-二氯苯基)丙酸 在 硼烷四氢呋喃络合物 、 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.25h， 生成 3-(3,5-二氯苯基)-丙醛
  参考文献：
  名称：

  Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site

  摘要：

  1-Aralkylimidazole-2-thiones have been shown to be potent multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1). In the present study, a series of 1-benzylimidazole-2-thiones was prepared to explore the effects of substitution in the benzyl ring on the inhibition of DBH. A detailed structure-activity relationship for in vitro activity was discovered and this was shown by a modified Hansch analysis to correlate (r = 0.91) with four key structural features of the benzyl ring: the presence of a hydroxyl at the 4-position, molar refractivity at the 3-, 4-, and 5-positions, inductive effects of the substituents at the 3-, 4-, and 5-positions, and pi-electron density. The affinity (Kis) of eight substituted inhibitors for DBH was shown to correlate (r = 0.75) with the affinity (KD) of comparably substituted tyramines for the ternary DBH-oxygen-tyramine complex. This correlate is used to support the hypothesis that binding of inhibitor to DBH occurs in a fashion that mimics the binding of tyramine substrates. The most potent inhibitors were selected for study in vivo in the spontaneously hypertensive rat model of hypertension. The changes in vascular dopamine and norepinephrine levels that resulted from oral administration of the inhibitors corresponded to the observed reduction in mean arterial blood pressure. A divergence between in vitro potency and in vivo efficacy upon oral dosing was noted and is suggested to result from an in vivo metabolic conjugation of the phenolic group of inhibitor.

  DOI：

  10.1021/jm00386a008

文献信息

• Photocatalytic Reductive Radical‐Polar Crossover for a Base‐Free Corey–Seebach Reaction
  作者：Karsten Donabauer、Kathiravan Murugesan、Urša Rozman、Stefano Crespi、Burkhard König

  DOI：10.1002/chem.202003000

  日期：2020.10.9

  abstraction of a hydrogen atom followed by radical reduction. The generated nucleophilic intermediate is then capable of adding to carbonyl electrophiles. The obtained dithiane can be easily converted to the valuable α‐hydroxy carbonyl in a subsequent step. The proposed reaction mechanism is supported by emission quenching, radical–radical homocoupling and deuterium labeling studies as well as by calculated

  在有机合成中，无金属的碳负离子亲核体的产生至关重要。本文中，我们报告了一种对Corey–Seebach反应的光催化方法。提出的方法在温和的氧化还原中性和无碱条件下运行，从而提供具有高官能团耐受性的所需产品。通过光和氢原子转移（HAT）催化的组合可以实现反应。这种催化合并使CH可以通过夺取氢原子然后进行自由基还原来进行碳负离子活化。然后，所产生的亲核中间体能够加成至羰基亲电子体。在随后的步骤中，可以很容易地将获得的二噻吩转化为有价值的α-羟基羰基。所提出的反应机理得到了发射猝灭的支持，
• [EN] EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RECEPTEURS D'ACIDES AMINES EXCITATEURS
  申请人：ELI LILLY AND COMPANY

  公开号：WO1996007405A1

  公开（公告）日：1996-03-14

  (EN) The present invention provides compounds of formula (I) in which R is as defined in the specification, or a pharmaceutically acceptable metabolically labile ester or amide thereof, or a pharmaceutically acceptable salt thereof, which are useful as antagonists of one or more of the actions of L-glutamate at metabotropic excitatory amino acid receptors.(FR) Cette invention concerne des composés de formule (I), dans laquelle R est tel que défini dans le descriptif, ou un ester ou amide pharmaceutiquement acceptable de ces composés qui est métaboliquement labile, ou encore un sel pharmaceutiquement acceptable de ces composés, qu'on utilise comme antagonistes d'une ou de plusieurs actions du L-glutamate au niveau des récepteurs d'acides aminés excitateurs métabotropiques.

  本发明提供了公式（I）的化合物，其中R如规范中定义，或其药物可接受的代谢易裂解酯或酰胺，或其药物可接受的盐，这些化合物是L-谷氨酸在代谢型兴奋性氨基酸受体上的一个或多个作用的拮抗剂。
• Chlorobenzene derivatives, liquid-crystal composition, and liquid-crystal display elements
  申请人：Chisso Corporation

  公开号：US06329027B1

  公开（公告）日：2001-12-11

  Provided are liquid crystalline compounds having excellent physical properties and being excellent in miscibility with other liquid crystal materials; liquid crystal compositions comprising the crystalline compound; and liquid crystal display device fabricated by using the liquid crystal composition; the liquid crystalline compounds being specific chlorobenzene derivatives expressed by the general formula (1) Ra—A1—Z1—A2&Parenopenst;Z2—A3&Parenclosest;m&Parenopenst;Z3—A4&Parenclosest;nRb  (1) wherein Ra, Rb, A1 to A4, Z1 to Z3, m, and n are herein defined.

  提供具有优异物理性能且与其他液晶材料混溶性优异的液晶化合物；包括所述晶体化合物的液晶组合物；以及使用所述液晶组合物制造的液晶显示装置；所述液晶化合物是由通式（1）所表示的特定氯代苯衍生物 Ra—A1—Z1—A2（Z2）—A3（Z3）—A4—Rb  (1) 组成，其中Ra，Rb，A1到A4，Z1到Z3，m和n在此定义。
• Photoexcited Ni^II–Aryl Complex-Mediated Giese Reaction of Aryl Bromides
  作者：Xian-Chen He、Ke-Rong Li、Jie Gao、Jian-Ping Guan、Hong-Bin Chen、Hao-Yue Xiang、Kai Chen、Hua Yang

  DOI：10.1021/acs.orglett.3c01219

  日期：2023.6.9

  Giese reaction of aryl bromides with electron-deficient alkenes was developed, enabled by a dual catalyst system containing NiII complex and IrIII photocatalyst. This protocol could accommodate a variety of aryl bromides and electron-deficient alkenes, delivering the conjugate adducts in up to 97% yield. The utilization of photoexcited (dtbbpy)NiII(aryl)Br intermediate as an aryl radical source allows

  开发了芳基溴化物与缺电子烯烃的 Giese 反应，该反应由包含 Ni II络合物和 Ir III光催化剂的双催化剂体系实现。该协议可以容纳各种芳基溴化物和缺电子烯烃，以高达 97% 的产率提供共轭加合物。利用光激发的 (dtbbpy)Ni II (芳基)Br 中间体作为芳基自由基源，可以实现芳基卤化物的这种新型转化，从而扩大激发镍催化的化学空间。
• Dopamine-beta-hydroxylase inhibitors
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0125033A1

  公开（公告）日：1984-11-14

  Compounds of formula:- wherein X is -H, -OH, halogen, C1-48alkyl, -CN, NO2, -SO2NH2, -CO2H, -CONH2, -CHO, -CH2OH. -CF3, -OCH3, -SO2C1-4alkyl, -SO2C1-4fluoroalkyl, or-CO2C1-4alkyl or any accessible combination thereof up to four substituents; Y is -H, -OH, halogen, C1-4alkyl, -CN, -NOz, -SO2NH2, -COzH, -CONH2, -CHO, -CHzOH, -CF3, -SO2C1-4alkyl, -SO2C1-4afiuoroalkyl, or -CO2C1-4alkyl; and R is -H or C1-4alkyl; and, n is 0-4, intermediates and processes for their preparation, pharmaceutical compositions containing them and their use in inhibiting DBH activity in mammals are described.

  式中化合物 式中 X是-H、-OH、卤素、C1-48烷基、-CN、NO2、-SO2NH2、-CO2H、-CONH2、-CHO、-CH2OH。-CF3、-OCH3、-SO2C1-4烷基、-SO2C1-4氟烷基或-CO2C1-4烷基或其中最多四个取代基的任何可获得的组合； Y 是-H、-OH、卤素、C1-4烷基、-CN、-NOz、-SO2NH2、-COzH、-CONH2、-CHO、-CHzOH、-CF3、-SO2C1-4烷基、-SO2C1-4氟烷基或-CO2C1-4烷基；以及 R 是-H 或 C1-4 烷基；以及 n 为 0-4、 所述中间体及其制备工艺、含有这些中间体的药物组合物以及它们在抑制哺乳动物体内 DBH 活性方面的用途。